TOP TEN perturbations for 1171_s_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1171_s_at
Selected probe(set): 227254_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1171_s_at (227254_at) across 6672 perturbations tested by GENEVESTIGATOR:

zalypsis study 2 / untreated OPM1 cell sample

Relative Expression (log2-ratio):-2.7146158
Number of Samples:2 / 2
Experimental zalypsis study 2
OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:---
Control untreated OPM1 cell sample
OPM1 multiple myeloma cells untreated.

oxyphilic adenoma study 1 / normal kidney tissue

Relative Expression (log2-ratio):-1.8344154
Number of Samples:4 / 2
Experimental oxyphilic adenoma study 1
Tumor tissue samples from the kidney of patients with oxyphilic adenoma (renal oncocytoma).
Control normal kidney tissue
Normal fetal kidney tissue samples.

bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)

Relative Expression (log2-ratio):-1.7848082
Number of Samples:2 / 2
Experimental bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondroblastic osteosarcoma of the bone (subcutaneously implanted).
Control bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted).

collecting duct carcinoma study 1 / normal kidney tissue

Relative Expression (log2-ratio):-1.7826824
Number of Samples:2 / 2
Experimental collecting duct carcinoma study 1
Tumor tissue samples from the kidney of patients with collecting duct carcinoma (CDC).
Control normal kidney tissue
Normal fetal kidney tissue samples.

stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)

Relative Expression (log2-ratio):1.7721739
Number of Samples:3 / 4
Experimental stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast)
Proerythroblast differentiated from IRF6 (interferon regulatory factor 6) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF6 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.
Control stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.

heat shock study 1 (LPS) / untreated THP-1 cell sample

Relative Expression (log2-ratio):-1.7662659
Number of Samples:3 / 3
Experimental heat shock study 1 (LPS)
Cultured THP-1 mononuclear cells were treated with heat shock (43°C; 1h) and lipopolysaccharide (1ug/ml; 4h).
Control untreated THP-1 cell sample
Cultured THP-1 mononuclear cells were cultured in basal growth media at 37°C.

glioma study 17 (glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):-1.7120199
Number of Samples:3 / 3
Experimental glioma study 17 (glioblastoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 66 ± 5 years old males.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

zalypsis study 1 / untreated MM1S cell sample

Relative Expression (log2-ratio):-1.7012978
Number of Samples:2 / 2
Experimental zalypsis study 1
MM1S multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:---
Control untreated MM1S cell sample
MM1S multiple myeloma cells untreated.

peptidoglycan study 1 / mock treated neonatal neutrophils

Relative Expression (log2-ratio):-1.7008934
Number of Samples:3 / 3
Experimental peptidoglycan study 1
Healthy neonatal neutrophils with ≥ 99% purity isolated from cord blood samples collected after normal, full-term, vaginal delivery treated with peptidoglycan isolated from S. aureus (10 ug/ml) for 4 hours.
Control mock treated neonatal neutrophils
Healthy neonatal neutrophils with ≥ 99% purity isolated from cord blood samples collected after normal, full-term, vaginal delivery mock treated for 4 hours.

Burkitt lymfoma study 4 (MAP2K inhibitor) / Burkitt lymfoma study 4 (control)

Relative Expression (log2-ratio):1.6280756
Number of Samples:3 / 5
Experimental Burkitt lymfoma study 4 (MAP2K inhibitor)
BL-2 cell line with activated B cell receptor (BCR) through αIgM treatment and isolated after MAP2K inhibition. A reduced expression of BCR.1 genes after BCR activation was observed and this activation led to a delayed entry to and progression of mitosis and defects in metaphase.
Control Burkitt lymfoma study 4 (control)
BL-2 cell line with activated B cell receptor (BCR) through αIgM treatment. A reduced expression of BCR.1 genes after BCR activation was observed and this activation led to a delayed entry to and progression of mitosis and defects in metaphase.